- Home
- IMMX vs STRO Comparison
IMMX vs STRO Comparison
Compare IMMX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- STRO
- Stock Information
- Founded
- IMMX 2014
- STRO 2003
- Country
- IMMX United States
- STRO United States
- Employees
- IMMX N/A
- STRO N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMMX Health Care
- STRO Health Care
- Exchange
- IMMX Nasdaq
- STRO Nasdaq
- Market Cap
- IMMX 65.5M
- STRO 74.3M
- IPO Year
- IMMX 2021
- STRO 2018
- Fundamental
- Price
- IMMX $2.00
- STRO $0.89
- Analyst Decision
- IMMX Strong Buy
- STRO Hold
- Analyst Count
- IMMX 1
- STRO 7
- Target Price
- IMMX $8.00
- STRO $1.97
- AVG Volume (30 Days)
- IMMX 183.0K
- STRO 514.4K
- Earning Date
- IMMX 11-11-2025
- STRO 11-12-2025
- Dividend Yield
- IMMX N/A
- STRO N/A
- EPS Growth
- IMMX N/A
- STRO N/A
- EPS
- IMMX N/A
- STRO N/A
- Revenue
- IMMX N/A
- STRO $104,473,000.00
- Revenue This Year
- IMMX N/A
- STRO $65.42
- Revenue Next Year
- IMMX N/A
- STRO N/A
- P/E Ratio
- IMMX N/A
- STRO N/A
- Revenue Growth
- IMMX N/A
- STRO N/A
- 52 Week Low
- IMMX $1.26
- STRO $0.52
- 52 Week High
- IMMX $3.20
- STRO $4.60
- Technical
- Relative Strength Index (RSI)
- IMMX 48.92
- STRO 48.88
- Support Level
- IMMX N/A
- STRO $0.85
- Resistance Level
- IMMX $2.34
- STRO $1.01
- Average True Range (ATR)
- IMMX 0.15
- STRO 0.09
- MACD
- IMMX -0.08
- STRO -0.01
- Stochastic Oscillator
- IMMX 85.11
- STRO 12.61
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.